By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CyDex, Inc. 

12980 Metcalf Avenue, Suite 470

Overland Park  Kansas  66213  U.S.A.
Phone: 913-685-8850 Fax: 913-685-8856


SEARCH JOBS



Segment
Drug Delivery

Collaborations

TargeGen, Inc.  Licensing Agreement





Company News
Ligand Pharmaceuticals Inc. (LGND) Buys CyDex, Inc. For $31.2M Upfront In Cash 1/27/2011 6:36:02 AM
CyDex, Inc. Announces New Corporate Name 11/20/2007 10:56:43 AM
Pediatric Asthma Programs With CyDex, Inc. Captisol Technology Acquired by AstraZeneca PLC (AZN) 10/3/2007 8:52:08 AM
Aradigm Corporation (ARDM) and CyDex, Inc. Sign Development Collaboration Agreement 9/6/2007 10:58:43 AM
CyDex, Inc. Licenses Captisol(R) to Critical Therapeutics for Injectable Formulation of Zileuton 6/12/2007 2:12:35 PM
CyDex, Inc. Licenses Captisol(R) to Sunesis Pharmaceuticals, Inc. (SNSS) for Oncology Drug Candidate 5/3/2007 12:20:17 PM
CyDex, Inc. Licenses Captisol(R) to Proteolix, Inc. for Promising Oncology Compound 5/1/2007 12:23:23 PM
CyDex, Inc. Announces Captisol Technology Used in Injection Formulation of Veterinary Anti-Emetic Cerenia(R) (Maropitant) Recently Approved for Marketing in Europe 4/10/2007 12:32:50 PM
CyDex, Inc. Announces Captisol Technology Used In Recently Launched Injection Formulation Of Antipsychotic Medication ABILIFY(R) (aripiprazole) 12/18/2006 3:49:17 PM
CyDex, Inc. Announces Captisol Technology Used In Recently Launched Injection Formulation Of Antipsychotic Medication ABILIFY(R) (aripiprazole) 12/14/2006 11:35:10 AM
12
//-->